AstraZeneca: Andexxa Phase IV Trial Stopped Early After Achieving Pre-Specified Criteria on Hemostatic Efficacy Versus Usual Care
June 07, 2023
June 07, 2023
WILMINGTON, Delaware, June 7 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of ANDEXXA (andexanet alfa) in patients on oral FXa inhibitor treatment including apixaban and rivaroxaban experiencing an intracranial hemorrhage, will be stopped early.1 The decision is based on achieving pre-specified stopping criteria of superior hemostatic efficacy, the ability to limit the expan . . .
ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of ANDEXXA (andexanet alfa) in patients on oral FXa inhibitor treatment including apixaban and rivaroxaban experiencing an intracranial hemorrhage, will be stopped early.1 The decision is based on achieving pre-specified stopping criteria of superior hemostatic efficacy, the ability to limit the expan . . .